Clinical Efficacy of Renal Failure Enema as an Adjuvant Therapy for Chronic Kidney Disease Stages 3-4 and Its Effect on Blood IS， PCS， and TMAO
10.13422/j.cnki.syfjx.20250495
- VernacularTitle:肾衰灌肠液辅助治疗慢性肾脏病3~4期的临床疗效及对血清IS、PCS、TMAO的影响
- Author:
Jing WANG
1
;
Mianzhi ZHANG
2
Author Information
1. Tianjin University of Traditional Chinese Medicine（TCM），Tianjin 300193，China
2. Affiliated Hospital of Tianjin Institute of TCM，Tianjin 300120，China
- Publication Type:Journal Article
- Keywords:
renal failure enema;
chronic kidney disease;
observation of therapeutic effect;
uremic toxin
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(6):164-170
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the clinical efficacy of renal failure enema for retention enema as an adjuvant therapy in patients with chronic kidney disease stages 3-4 and its effect on serum uremic toxins including indoxyl sulfate （IS），p-cresol sulfate （PCS），and trimethylamine oxide （TMAO）. MethodsA total of 60 patients with stage 3-4 chronic kidney disease in the Department of Nephrology，Affiliated Hospital of Tianjin Institute of Traditional Chinese Medicine from June 2023 to November 2023，were divided into a control group and an observation group. Each group consisted of 30 patients，and the random number table method was used for the division. Both groups received routine symptomatic treatment of traditional Chinese medicine （TCM） and Western medicine in the department. The observation group，based on the treatment of the control group，was additionally given 100-200 mL of the hospital-made renal failure enema capsules once every other day. The total treatment course was 4 weeks. The changes in serum creatinine （SCr），blood urea nitrogen （BUN），uric acid （UA），24-hour urine total protein quantification （24 h UTP），and serum uremic toxins such as IS，PCS，and TMAO were compared between the two groups before and after treatment. The total clinical effective rate of TCM and Western medicine was calculated and the adverse reactions were recorded. ResultsBefore treatment，the baseline levels of the two groups were comparable. After treatment，the total effective rate of the observation group （80.0%，24/30） was superior to that of the control group （53.3%，16/30），and the difference was statistically significant （Z=2.267，P=0.023）. After treatment，the TCM pattern scores of the two groups were lower than before，and the constipation symptoms in the observation group were improved（P<0.01）. Compared with the control group after treatment，the observation group showed decreased TCM syndrome scores，and the difference before and after treatment was larger （P<0.05）. Compared with before treatment，the SCr in both groups decreased after treatment （P<0.05）. BUN levels decreased in the observation group（P<0.05），and IS and PCS levels decreased in the observation group（P<0.05，P<0.01）. Compared with the control group after treatment，the IS level of the observation group decreased （P<0.05）. During the trial，no adverse reactions occurred in either group. ConclusionRenal failure enema can be used as an adjuvant therapy for patients with CKD stages 3-4. It can not only slow down the progression of renal function but also effectively down-regulate the levels of uremic toxins. In addition，it can significantly improve the TCM syndrome of kidney disease patients，which makes it worthy of clinical application and promotion.
